{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-046395","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2023-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.013056+00:00","generated_at":"2026-06-07T06:29:29.777460+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PowerUp Acquisition Corp. enters merger with Visiox Pharmaceuticals for $80M base consideration","bullets":["Base merger consideration of $80M, subject to net working capital, transaction expenses, and indebtedness adjustments.","Earnout: up to 6M additional shares tied to Omlonti first commercial sale within 12 months and stock price targets of $12.50 and $15.00.","Post-closing board: 5 directors (2 from PowerUp, 3 from Visiox); CEO and CFO will be Visiox's executives.","Closing conditions include net tangible assets >= $5,000,001 and at least $5M in trust or PIPE after redemptions; Outside Date May 31, 2024.","Also disclosed $250K loan from SSVK Associates to sponsor, then to PowerUp, repayable in cash or shares at $10/share conversion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-046395","json":"https://secwatch.observer/filing/0001493152-23-046395.json","markdown":"https://secwatch.observer/filing/0001493152-23-046395.md","text":"https://secwatch.observer/filing/0001493152-23-046395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223046395/0001493152-23-046395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223046395/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:29:29.777460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ce7cdadf1f98225c4ca333dfb095b3a627d0616","claim":"Aspire Biopharma Holdings, Inc. entered into Agreement and Plan of Merger with PowerUp Acquisition Corp., PowerUp Merger Sub Inc., SRIRAMA Associates, LLC, Visiox Pharmaceuticals, Inc., Ryan Bleeks valued at $80,000,000 (effective 2023-12-26).","evidence_excerpt":"On December 26, 2023, PowerUp Acquisition Corp., a Cayman Islands exempted company (“PowerUp” or “Purchaser”), entered into an Agreement and Plan of Merger by and among PowerUp, PowerUp Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of PowerUp (“Merger Sub”), SRIRAMA Associates, LLC, a Delaware limited liability company and PowerUp’s sponsor (the “Sponsor”), Visiox Pharmaceuticals, Inc., a Delaware corporation (“Visiox” or “Seller”), and Ryan Bleeks, in the capacity as the seller representative (as may be amended and/or restated from time to time, the “Merger Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223046395/0001493152-23-046395-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"PowerUp Acquisition Corp., PowerUp Merger Sub Inc., SRIRAMA Associates, LLC, Visiox Pharmaceuticals, Inc., Ryan Bleeks"},{"label":"Value","value":"$80,000,000"},{"label":"Effective","value":"2023-12-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}